Prostate Cancer Drug May Delay Time to Second-Line Treatment

Share this content:

Degarelix may delay time to second-line therapy and improve PSA control and in men with advanced hormone-dependent prostate cancer, according to long-term data from an extension study. John Schieszer has the story in today's Medical Minute.
You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters